Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
Bellmunt
Joaquim
J
Medical Oncology Service, University Hospital Del Mar, Paseo Maritimo 25-29, Barcelona, Spain. jbellmunt@imas.imim.es
Delgado
Francois-Michel
FM
George
Claude
C
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy; D051379:Mice; D010997:Pleural Neoplasms / Q000188:drug therapy; D050257:Tubulin Modulators / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms; D019459:Urothelium; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D050257:Tubulin Modulators; C111217:vinflunine; D014747:Vinblastine